Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612000157875
Ethics application status
Approved
Date submitted
1/02/2012
Date registered
3/02/2012
Date last updated
25/07/2019
Date data sharing statement initially provided
25/07/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
Effects of L-DOPS in Patients with Low- and Normal- Blood Pressure Variants of Orthostatic Intolerance.
Scientific title
Effects of L-DOPS on Noradrenaline Responses to Head-up Tilt in patients with Low- and Normal- Supine Blood Pressure Variant of Orthostatic Intolerance.
Secondary ID [1] 279842 0
Nil known
Universal Trial Number (UTN)
U1111-1127-6367
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Orthostatic Intolerance 285722 0
Vasovagal Syncope 285723 0
Neurally Mediated Syncope 285724 0
Condition category
Condition code
Cardiovascular 285907 285907 0 0
Diseases of the vasculature and circulation including the lymphatic system
Neurological 285939 285939 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This study is investigating the use of L-DOPS (L-threo-dihydroxyphenylserine), a Noradrenaline precursor, in pateints with Orthostatic Intolerance.
The study design involves a baseline assessment of 24 -hour blood pressure and symptoms. Noradrenline kinetics and muscle sympathetic responses to head-up tilt are measured. A vein biopsy is performed to assess sympathetic nerve noradrenaline content.
A group of healthy controls with be recruited for comparison of baseline data only.
In the two Orthostatic Intolerance groups the baseline evaluation is followed by a 21-28 day tolerability and dose titration period. During this period there is open label adminstration of L-DOPS (oral tablets three times/day) to determine the maximum tolerated daily dose (range 300-1800mg/day) prior to a double blind placebo controlled randomisation phase.
The randomised double-blind crossover clinical evaluation of L-DOPS involves an oral tablet (active or placebo) given three times daily at the patient specific dose (range 300-1800 mg/day) determined during the open label titration period. There are two randomised 28 day dosing periods. Clinical evaluation of symptoms is performed at the conclusion of the 28 days, evaluating the final 14 days of each dosing period. The first 14-days of each period acts as a 'washout' period. Clinical evaluation includes symptom assessment and 24-hour blood pressure monitoring.
At the conclusion of the randomised double blind placebo controlled clinical evaluation period open label L-DOPS (oral tablet three times/day at the patient specific dose previously determined, range 300-1800mg/day) is given for 21 days prior to repeating a head-up tilt table test with evaluation of noradrenaline kinetics and muscle sympathetic nerve recording followed by a repeat vein biopsy.
Intervention code [1] 284162 0
Treatment: Drugs
Comparator / control treatment
Placebo - for randomised double blind crossover evaluation. Idendical tablets provided by the manufacturer of L-DOPS
Control group
Placebo

Outcomes
Primary outcome [1] 286404 0
50% augmentation in noradrenaline spillover at 40 degree head-up tilt following L-DOPS dosing compared with baseline.
Noradrenaline spillover is measured using a radioisotope dilution method. Radioisotope labelled noradrenaline is infused intravenously and blood samples taken from an indwelling brachial arterial catheter. Samples are taken after 30 minutes of supine rest after infusion initiation and at the conclusion of 10minutes head-up tilt at 20, 30, 40 and 60 degrees. Samples are analysed using high performance liquid chromatography (HPLC). Noradrenaline spillover is calculated from raw noradrenaline values after adjustment for the changes in noradrenaline clearance that occur during head-up tilt as calculated using the radioisotope dilution method.
Timepoint [1] 286404 0
Baseline and after a minimum of 21 days open label dosing with L-DOPS following a randomised double-blind placebo controlled clinical evaluation.
Primary outcome [2] 286405 0
At baseline: 50% lower noradrenaline spillover at 40 degree head-up tilt in patients with Orthostatic Intolerance compared with healthy controls.
Noradrenaline spillover is measured using a radioisotope dilution method. Radioisotope labelled noradrenaline is infused intravenously and blood samples taken from an indwelling brachial arterial catheter. Samples are taken after 30 minutes of supine rest after infusion initiation and at the conclusion of 10minutes head-up tilt at 20, 30, 40 and 60 degrees. Samples are analysed using high performance liquid chromatography (HPLC). Noradrenaline spillover is calculated from raw noradrenaline values after adjustment for the changes in noradrenaline clearance that occur during head-up tilt as calculated using the radioisotope dilution method.
Timepoint [2] 286405 0
Baseline head-up tilt test.
Secondary outcome [1] 295788 0
Functional status as assessed using the Orthostatic Hypotension symptom Assessment (OHSA), Orthostatic Hypotension Daily Activities Scale(OHDAS) and SF-36 Quality of Life Assessment Instrument.
Timepoint [1] 295788 0
At baseline and at the conclusion of each the two 28 day clinical evaluation periods of the randomised double-blind placebo controlled crossover phse of the study.

Eligibility
Key inclusion criteria
Participants with Orthostatic Intolerance

1.Age 18-50

2.Clinical disorder of orthostatic intolerance in association with syncope or recurrent presyncope.

a.An underlying medical condition causing these symptoms has been excluded, in particular structural heart disease, Addison’s disease and hypothyroidism.
b. Symptoms will have been present and occurring at least weekly for > or = 6 months. Symptoms include lightheadedness, weakness, blurred vision, syncope or presyncope.

3.Clinical Phenotype consistent with either Low- or Normal- Supine BP Vasovagal syncope;
a. Low- Supine Blood Pressure is defined as a typical (two or more BP readings by a medical practitioner) supine blood pressure of < or= 100 mmHg
b. Normal-Supine Blood Pressure is defined as a typical supine blood pressure of > or = 110 and < or = 140 mmHg

Healthy Control Participants for Basline comparison only ( no drug phase):

Aged between 18- 50 years.
No history of fainting or symptoms such as light-headedness, blurred vision, nausea or palpitations in association with standing.
Minimum age
18 Years
Maximum age
50 Years
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
Participants with Orthostatic Intolerance:
1. Age <18 or > 50
2. Pregnant or Breastfeeding women
3. Women of childbearing potential who are not using medically accepted contraception;
Reproductive potential: Female subjects should be either postmenopausal
(amenorrhea for at least 12 consecutive months), surgically sterile,
or women of child-bearing potential (WOCP) who are using or agree to use
acceptable methods of contraception. Acceptable contraceptives include
intrauterine devices (IUDs), hormonal contraceptives (oral, depot, patch or
injectable) and double barrier methods such as condoms or diaphragms with spermicidal gel or foam.

4. Sexually active males whose partner is a WOCP and who do not agree to use
condoms for the duration of the study and for 30 days after the last dose;

5. Inability to withhold pressor medications for the duration of the study. Pressor medications, (eg Fludrocortisone, Midodrine, Dihydroergotamine, Pseudoephedrine, Licorice Extract, Butcher’s Broom, Cold and Flu remedies, Diet pills, NSAIDs, pyridostigmine) must be ceased for 2 weeks prior to the commencement of the study and withheld for the entire duration of the study.

6. Antidepressant medications including: tricyclics and tetracyclic antidepressants, SSRI/ SNRI/ NRI’s, MAO inhibitors;

7. Medications known to lower blood pressure that cannot be withheld for the duration of the study, eg beta -blockers;

8. Presence of structural heart disease – including ischaemic heart disease.

9. Hypertension (supine SBP > or =140 mmHg)

10. Diabetes

11. Gastrointestinal illness that may impair absorption of the study drug.

12. Known or suspected hypersensitivity to the study medication or any of its ingredients;

13. In the investigator’s opinion, have clinically significant abnormalities on clinical examination or laboratory testing;

Healthy Control Participants:
Age<18 or >50 years
Necessary Medication other than the oral controaceptive pill
Pregnant or Breastfeeding

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Randomisation is performed through pharmacy and concealed from the investigators.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomisation. The randomisation table is created by computer software in pharmacy.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 2
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
15/02/2012
Actual
15/02/2012
Date of last participant enrolment
Anticipated
Actual
2/04/2014
Date of last data collection
Anticipated
Actual
15/08/2014
Sample size
Target
76
Accrual to date
Final
23
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 284609 0
Government body
Name [1] 284609 0
NHMRC
Country [1] 284609 0
Australia
Primary sponsor type
Charities/Societies/Foundations
Name
BakerIDI Heart and Diabetes Institute
Address
Baker IDI Heart and Diabetes Institute
PO Box 6492, St Kilda Road Central
Victoria 8008
Country
Australia
Secondary sponsor category [1] 283528 0
Hospital
Name [1] 283528 0
Alfred Health
Address [1] 283528 0
The Alfred

P.O Box 315
Prahran. Vic. 3181
Country [1] 283528 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 286604 0
Th Alfred Research and Ethics Committee
Ethics committee address [1] 286604 0
The Alfred Hospital,
55 Commercial Road,
Melbourne,
Victoria 3004
Ethics committee country [1] 286604 0
Australia
Date submitted for ethics approval [1] 286604 0
Approval date [1] 286604 0
23/11/2011
Ethics approval number [1] 286604 0
1/11/0395

Summary
Brief summary
Difficulty in maintaining the upright posture is called Orthostatic Intolerance. Orthostatic Intolerance may result in fainting or symptoms such as light-headedness, blurred vision, nausea and palpitations. These symptoms come on when standing or sitting, particularly for prolonged periods or time or in warm weather, and are relieved by lying down. They are often associated with an abnormal blood pressure or heart rate response to sitting or standing.

Our research to date has looked in detail at two clinical groups with these symptoms. Both of these groups have overall normal nervous system function, but with intermittent difficulty in maintaining the upright posture. One group always has very low blood pressure (Low Supine Blood Pressure Orthostatic Intolerance) and the other normal blood pressure (Normal Supine Blood Pressure Orthostatic Intolerance).

Our studies have particularly looked for differences in the way a part of the nervous system called the sympathetic nervous system responds to the upright posture in these two groups when compared to healthy control participants. The sympathetic nervous system, the stimulant arm of the nervous system is responsible for our “flight and fight” response to a threatening situation. The sympathetic nervous system is also crucial in the control of blood pressure and allows us to stand upright and supply blood to our vital organs, including the brain, in the face of gravity that pulls blood towards our legs.

We have found that people with these two forms of Orthostatic Intolerance do not release as much of the main chemical messenger of the sympathetic nervous system – called noradrenaline - into their circulation in response to upright posture when compared with healthy control participants. We have found distinct differences between these two groups and between each group and healthy control participants in the processing pathways for noradrenaline.

Current medical treatments for these forms of Orthostatic Intolerance have focused on increasing blood volume by increasing dietary salt or by the use of a medication (Fludrocortisone) that make the body retain salt and fluid. In addition medications that act to tighten blood vessels with standing (Midodrine or Dihydroergotamine) may also be used. These medications can be very helpful for some patients but are often not tolerated due to side effects and many patients continue to experience symptoms even with these medications. None of these medications has been proven to be of benefit in randomised trials to date.
This trial will be comparing a new treatment – L-DOPS (Droxidopa) – with placebo (a tablet that appears the same as the L-DOPS tablets but contains no active ingredients) in patients with the two forms of Orthostatic Intolerance described above. L-DOPS is a nerve transmitter precursor that is converted by the body to noradrenaline, the main nerve messenger of the sympathetic nervous system. L-DOPS is an experimental treatment. This means it is not approved for patients with Low- or Normal- supine blood pressure Orthostatic Intolerance in Australia or other parts of the world. L-DOPS has been marketed in Japan since 1989 for use in patients with Parkinson Disease and Orthostatic Intolerance. L-DOPS remains an investigational drug in the United States and Australia. Current trials in the United States and Canada are studying its benefit in blood pressure regulation disorders in Parkinson disease and in symptoms in patients with Chronic Fatigue syndrome and Fibromyalgia (a condition associated with painful muscles).

This study will include:

20 Healthy control Participants

28 Participants with Low supine Blood Pressure Orthostatic Intolerance

28 Participants with Normal Supine Blood Pressure Orthostatic Intolerance

All participants will be studied through the Alfred Baker Medical Unit at the Alfred Hospital

The purpose of this research is twofold:
1. The baseline assessment will compare the way the sympathetic nervous system responds to the ‘stress’ of the upright posture in healthy control participants and participants with the two different clinical presentations of Orthostatic Intolerance described above. These responses will be correlated with the individual pattern of nerve proteins and nerve transmitter levels - obtained from a forearm vein biopsy- in the participants. This part of the study is to being performed to confirm our previous findings in a larger group of participants and to provide baseline measurements for the participants with Orthostatic Intolerance who will participate in the second phase of the study.
2. The second phase of the study is to assess whether the nerve transmitter replacement L-DOPS(Droxidopa) is able to improve symptoms and normalise the sympathetic nervous system response to upright posture in participants with the low- and normal- supine blood pressure variants of Orthostatic Intolerance.
Trial website
Trial related presentations / publications
Publications in preparation
Public notes

Contacts
Principal investigator
Name 33711 0
Prof Murray Esler
Address 33711 0
Human Neurotransmitters Laboratory BakerIDI PO Box 6492, St Kilda Road Central Victoria 8008
Country 33711 0
Australia
Phone 33711 0
+61 3 8532 1111
Fax 33711 0
Email 33711 0
[email protected]
Contact person for public queries
Name 16958 0
Dr Susan Corcoran
Address 16958 0
Human Neurotransmitters Laboratory
BakerIDI
PO Box 6492,
St Kilda Road Central
Victoria 8008
Country 16958 0
Australia
Phone 16958 0
+61 3 85321111
Fax 16958 0
Email 16958 0
[email protected]
Contact person for scientific queries
Name 7886 0
Dr Susan Corcoran
Address 7886 0
Human Neurotransmitters Laboratory
BakerIDI
PO Box 6492,
St Kilda Road Central
Victoria 8008
Country 7886 0
Australia
Phone 7886 0
+61 3 8532 1111
Fax 7886 0
Email 7886 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Individual data may be made available if requested. Trail commenced in 2012 and recruitment completed in 2014. the consent form did not cover public sharing of data from the study.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.